Analysis of Prognostic Factors of PFS
| Univariate analysis | Multivariate analysis | |||||
| Variable | Median PFS (mo) | 95% CI | P | HR | 95% CI | P |
| Primary tumor origin | 0.013 | 0.003 | ||||
| Gallbladder cancer | 5.3 | 2.8–7.8 | 0.476 | 0.17–1.32 | ||
| IHCC | 8.3 | 5.0–11.6 | Ref | |||
| EHCC | 5.0 | 2.2–7.8 | 2.31 | 0.83–6.50 | ||
| AoV cancer | 1.3 | 0.7–1.9 | 3.26 | 0.83–12.85 | ||
| c-Myc | 0.044 | |||||
| Negative | 7.0 | 2.5–11.5 | ||||
| Positive | 3.8 | 0.4–7.2 | ||||
| Initial SUVmax | 0.002 | 4.09 | 1.73–9.66 | 0.001 | ||
| ≤9.0 | 7.0 | 4.8–9.2 | ||||
| >9.0 | 3.8 | 2.2–5.4 | ||||
| SUVmax reduction (at best 18F-FDG PET response) | <0.001 | 3.35 | 1.55–7.20 | 0.002 | ||
| ≥20.0% | 8.8 | 5.8–11.8 | ||||
| <20.0% | 3.9 | 3.3–4.5 | ||||
| Organs with 18F-FDG uptake (n) | 0.134 | |||||
| 0–2 | 6.3 | 4.8–7.9 | ||||
| ≥3 | 3.9 | 2.2–5.6 | ||||